Back to search results

Comparing Pain Control Methods in Gynecologic Oncology Surgery

This study is comparing two ways to manage pain after gynecologic oncology surgery: a transversus abdominis plane (TAP) block and local anesthetic wound infiltration. The TAP block involves injecting 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine on each side of your abdomen. The wound infiltration uses 266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in saline, injected into the surgical area. Researchers want to see which method leads to less opioid pain medication use in the first 24 hours after surgery. You may be eligible if you are an English-speaking woman over 18, undergoing exploratory laparotomy (abdominal surgery) for gynecologic reasons at UW Hospital and Clinics, and can provide consent. The study aims to enroll 80 participants. The current recruitment status is unclear.

Study design
This is an interventional study comparing two different pain control methods. It plans to enroll 80 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Opioid use is measured for the first 24 hours post-surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06213454

Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery

Active, Not Recruiting
PHASE4Ages 18+InterventionalSupportive care
University of Wisconsin, Madison
~82 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:TAP AnesthesiaSurgeon-Initiated Local Anesthetic

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total opioid use measured in oral morphine equivalents for the first 24 hours post-surgery
Measured over 24 hours post-surgery

Conditions

Analgesia
Surgery

Explore related trials

Malignant Female Reproductive System Neoplasm

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Sumer Wallace, MD · PRINCIPAL_INVESTIGATOR · UW Carbone Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to understand and the willingness to sign a written informed consent document
Patients undergoing exploratory laparotomy via midline vertical skin incision for gynecologic indications at UW Hospital and Clinics
Patients must be \>18 years old
English speaking (able to provide consent and complete questionnaires)
Patients must have the ability to understand visual and verbal pain scales
Patients must be eligible for TAP block placement. This will be confirmed during preoperative visit with the primary surgeon. Patient's are not eligible if they have allergies to the anesthetic medications or have had prior abdominal reconstructive surgery that would alter their abdominal wall anatomy in a way where the block would not be expected to be effective.

Exclusion

Known allergy to local anesthetics.
Known history of chronic pain disorders and/or chronic opioid use defined as greater than 10mg of PO morphine or equivalent used daily for at least 30 days prior to enrollment.
Patient has a history of opioid dependence requiring rehabilitation or the use of opioid antagonists.
Patients with a planned exploration with biopsies (no organs removed) will be excluded from the study.
Individuals who are pregnant, lactating or planning on becoming pregnant during the study.
Significant liver disease that would inhibit prescription of opioids.
Significant kidney disease that would inhibit administration of gabapentin.
Not suitable for study participation due to other reasons at the discretion of the investigators.

What this trial measures

  • Total opioid use measured in oral morphine equivalents for the first 24 hours post-surgery24 hours post-surgery

    Total opioid use measured in oral morphine equivalents for the first 24 hours post-surgery (including intraoperative and Post Anesthesia Care Unit (PACU) opioid utilization).